ArticleFrontiers in immunology2026
Immunometabolic interactions in individuals with down syndrome across childhood, adolescence and adulthood in relation to their siblings.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and aim: Down syndrome is the most common chromosomal disorder characterized by a wide spectrum of clinical symptoms such as immune system dysregulation and co-occurring metabolic disorders, including an increased risk of cardiovascular disease. Therefore, the aim of this study was to evaluate the immunometabolic interactions in children adolescents and adults with Down syndrome (DS) and to compare selected inflammatory and metabolic parameters with those observed in their siblings. Materials and methods: The study included n= 63 individuals who were divided into two groups: group with DS n=42 (mean age: 14.2 ± 6.6) and control group (CG) n=21 (mean age: 15.6 ± 6.9). In addition, patients in both groups were also divided according to age ≤ 18 years and >18 years of age. Carbohydrate-lipid and immunological profiles were analyzed using spectrophotometric and immunoenzymatic methods. Statistical analysis was performed using R studio software. Results: In the DS group ≤ 18 years significantly higher obesity rates, i.e., Ponderal Mass Index (TMI), were observed (p=0.04), which was also associated with statistically significantly higher level of non-HDL (p=0.02) and apoB (p=0.04). Among lipid parameters, apolipoprotein A demonstrated relatively high diagnostic utility (AUC = 0.818, sens%=60.0, spec%=95.2). Significantly lower cytokine levels were observed in the DS group for IL-10 (p=0.006), IL-13 (p<0.01), and IL-22 (p=0.002). The highest diagnostic utility among the assessed cytokines was demonstrated for IL-5 (AUC = 0.814, sens%=71.10, spec%=88.1). Conclusion: The analyses conducted indicate significant differences between the studied groups of patients with Down syndrome and the control group. The presence of an additional copy of 21 the chromosome leads to changes in the immune system, influences the heterogeneous cytokine profile, and consequently may increase the development of metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.